Olatec Therapeutics set to launch dapansutrile Phase 2 trial in Parkinson’s disease

Olatec Therapeutics, Inc. (Olatec), a leader in the field of selective NLRP3 inhibitors, has embarked on a  journey to tackle Parkinson's disease, a neurodegenerative disorder ... Read More